{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:09:51Z","timestamp":1790359791495,"version":"4.1.0"},"reference-count":96,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>Clinical management of metastatic melanoma suffered historically from a lack of effective targeted and immunotherapies due to short-lived clinical responses. Recent advances in our understanding of tumor-immune signaling pathways, discovery of immunosuppressive checkpoints, and subsequent development of antibodies that target these checkpoints reverses the situation to some extent. Two antibodies ipilimumab and nivolumab gained Food and Drug administration approval for the treatment of metastatic melanoma and target two major immunosuppressive checkpoints cytotoxic T lymphocyte antigen and programmed cell death protein 1 (PD-1), respectively. Nivolumab binds to PD-1, prevents PD-1 interaction with ligand Programmed death ligand 1 (PD-L1), and thus releases the T-cell exhaustion events (such as T cell apoptosis, decrease in T cell proliferation, etc.) leading to buildup of potent tumor-specific immune response. Successful Phase I\u2013III results with remarkable antitumor activity and safety led to approval of nivolumab against ipilimumab refractory metastatic melanoma. Nivolumab therapy is exciting in that it not only provides substantial benefit but also provides durable responses. This review focuses on the evolution of immunotherapy leading to nivolumab approval and its potential in treating melanoma either alone or in combination with other therapies.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_1290_16","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T07:55:13Z","timestamp":1523001313000},"page":"1167-1175","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":67,"title":["Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma"],"prefix":"10.4103","volume":"14","author":[{"given":"Veerendra","family":"Koppolu","sequence":"first","affiliation":[{"name":"Department of Molecular Biosciences, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veneela Krishna","family":"Rekha Vasigala","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Rangaraya Medical College, NTR University of Health Sciences, Vijayawada, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"R1-20260109","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R2-20260109","first-page":"845","article-title":"Treatment of melanoma","volume":"105","author":"Garbe","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/era.09.25","article-title":"Current systemic therapy for metastatic melanoma","volume":"9","author":"Agarwala","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ctrv.2015.05.012","article-title":"Gaining momentum: New options and opportunities for the treatment of advanced melanoma","volume":"41","author":"Michielin","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","article-title":"New drugs in melanoma: It's a whole new world","volume":"47","author":"Eggermont","year":"2011","journal-title":"Eur J Cancer"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2015.12.002","article-title":"The rapidly evolving therapies for advanced melanoma \u2013 Towards immunotherapy, molecular targeted therapy, and beyond","volume":"99","author":"Zhu","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv Immunol"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/j.seminoncol.2015.02.008","article-title":"Anti-PD-1 therapy in melanoma","volume":"42","author":"Homet Moreno","year":"2015","journal-title":"Semin Oncol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","article-title":"Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer","volume":"37","author":"Hughes","year":"2016","journal-title":"Trends Immunol"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2015.01.006","article-title":"The evolution of checkpoint blockade as a cancer therapy: What's here, what's next?","volume":"33","author":"Shin","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"00092","DOI":"10.15406\/moji.2016.03.00092","article-title":"CTLA-4 antibodies in cancer immunotherapy","volume":"3","author":"Koppolu","year":"2016","journal-title":"MOJ Immunol"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1758834014567469","article-title":"Nivolumab in melanoma: Latest evidence and clinical potential","volume":"7","author":"Johnson","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/13543784.2015.991819","article-title":"Nivolumab for the treatment of cancer","volume":"24","author":"Gunturi","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M","article-title":"Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer","volume":"83","author":"Kammula","year":"1998","journal-title":"Cancer"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00002371-200107000-00004","article-title":"Guidelines for the safe administration of high-dose interleukin-2","volume":"24","author":"Schwartzentruber","year":"2001","journal-title":"J Immunother"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2001.19.5.1430","article-title":"High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4137\/MBI.S10878","article-title":"Role of Escherichia coli in biofuel production","volume":"9","author":"Koppolu","year":"2016","journal-title":"Microbiol Insights"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1128\/IAI.00919-13","article-title":"Small-molecule inhibitor of the Shigella flexneri master virulence regulator virF","volume":"81","author":"Koppolu","year":"2013","journal-title":"Infect Immun"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J Exp Med"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1084\/jem.173.3.721","article-title":"Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation","volume":"173","author":"Linsley","year":"1991","journal-title":"J Exp Med"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking of T cells into tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/1087057112474690","article-title":"Identification of a small-molecule inhibitor of bacterial AraC family activators","volume":"18","author":"Skredenske","year":"2013","journal-title":"J Biomol Screen"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily \u2013 CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1479-5876-12-116","article-title":"Clinical experience with ipilimumab 3 mg\/kg: Real-world efficacy and safety data from an expanded access programme cohort","volume":"12","author":"Ascierto","year":"2014","journal-title":"J Transl Med"},{"key":"R42-20260109","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","article-title":"Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)","volume":"24","author":"McDermott","year":"2013","journal-title":"Ann Oncol"},{"key":"R43-20260109","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R45-20260109","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol"},{"key":"R46-20260109","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-09-2376","article-title":"Do we need a different set of response assessment criteria for tumor immunotherapy?","volume":"15","author":"Ribas","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R47-20260109","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R48-20260109","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"R49-20260109","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/excr.1997.3493","article-title":"Activation-induced expression of human programmed death-1 gene in T-lymphocytes","volume":"232","author":"Vibhakar","year":"1997","journal-title":"Exp Cell Res"},{"key":"R50-20260109","doi-asserted-by":"crossref","first-page":"10275","DOI":"10.1073\/pnas.0805459105","article-title":"Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek","volume":"105","author":"Freeman","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R51-20260109","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"R52-20260109","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"J Exp Med"},{"key":"R53-20260109","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"R54-20260109","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"R55-20260109","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1002\/eji.200324270","article-title":"Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur J Immunol"},{"key":"R56-20260109","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"R57-20260109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed death-1 pathway in cancer and autoimmunity","volume":"153","author":"Pedoeem","year":"2014","journal-title":"Clin Immunol"},{"key":"R58-20260109","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R59-20260109","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"R60-20260109","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1021\/acs.biochem.6b01244","article-title":"Decoding of O-linked glycosylation by mass spectrometry","volume":"56","author":"Mulagapati","year":"2017","journal-title":"Biochemistry"},{"key":"R61-20260109","first-page":"1","article-title":"Cancer immunotherapy arsenal: Current and promising new approaches","volume":"5","author":"Veerendra","year":"2017","journal-title":"Cancer Ther Oncol Int J"},{"key":"R62-20260109","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"15 suppl","key":"R63-20260109","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/jco.2014.32.15_suppl.3001","article-title":"A phase 1 study of MEDI4736, an anti\u2013PD-L1 antibody, in patients with advanced solid tumors","volume":"32","author":"Lutzky","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"R64-20260109","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1200\/jco.2013.31.15_suppl.9010","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (MM)","volume":"31","author":"Hamid","year":"2013","journal-title":"J Clin Oncol"},{"key":"R65-20260109","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"R66-20260109","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"R67-20260109","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J Exp Med"},{"key":"R68-20260109","doi-asserted-by":"crossref","first-page":"11823","DOI":"10.1073\/pnas.0505497102","article-title":"Establishment of NOD-pdcd1-\/- mice as an efficient animal model of type I diabetes","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R69-20260109","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"R70-20260109","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"R71-20260109","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.4049\/jimmunol.162.10.5784","article-title":"Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of th2 responses","volume":"162","author":"Khattri","year":"1999","journal-title":"J Immunol"},{"key":"R72-20260109","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R73-20260109","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/1753465816661091","article-title":"Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: A review of the evidence","volume":"10","author":"Lim","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"R74-20260109","first-page":"6501","article-title":"B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome","year":"2003","journal-title":"Cancer Res"},{"key":"R75-20260109","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"R76-20260109","first-page":"811","volume":"6","year":"2016","journal-title":"Cancer Discov"},{"key":"R77-20260109","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.seminhematol.2016.05.011","article-title":"Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results","volume":"53","author":"Younes","year":"2016","journal-title":"Semin Hematol"},{"key":"R78-20260109","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.seminoncol.2015.02.004","article-title":"Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies","volume":"42","author":"Bracarda","year":"2015","journal-title":"Semin Oncol"},{"key":"R79-20260109","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.124","article-title":"Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers","volume":"112","author":"Homet Moreno","year":"2015","journal-title":"Br J Cancer"},{"key":"R80-20260109","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R81-20260109","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"R82-20260109","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.alit.2016.04.009","article-title":"Severe pneumonitis after nivolumab treatment in a patient with melanoma","volume":"65","author":"Watanabe","year":"2016","journal-title":"Allergol Int"},{"key":"R83-20260109","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"R84-20260109","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R85-20260109","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"R86-20260109","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R87-20260109","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R88-20260109","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"R89-20260109","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.clon.2016.06.008","article-title":"Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis","volume":"28","author":"Abdel-Rahman","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R90-20260109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"R91-20260109","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"R92-20260109","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"R93-20260109","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"R94-20260109","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"R95-20260109","article-title":"A Randomized Controlled Comparison of Pembrolizumab and Chemotherapy in Patients with Ipilimumab-Refractory (IPI-R) Melanoma (MEL)","author":"Ribas","year":"2014","journal-title":"Late Breaking Abstract Presented at the 11th International Congress of the Society for Melanoma Research"},{"key":"R96-20260109","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R97-20260109","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201814060-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:01:38Z","timestamp":1786647698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201814060-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1290_16","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}